$ACT Recent Headlines Eight charts plot the ye
Post# of 102233
Posted On: 12/30/2014 12:15:52 PM
$ACT Recent Headlines
Eight charts plot the year in finance 6:00 a.m. Today - Ophir Gottlieb
Here are the best S&P 500 stocks and sectors of 2014 1:52 p.m. Dec. 29, 2014 - Philip van Doorn
2014 was the year that all predictions were wrong 11:29 a.m. Dec. 26, 2014 - Marek Fuchs
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Adamas' stock soars after dementia treatment approval 8:24 a.m. Dec. 24, 2014 - Tomi Kilgore
Second 2% S&P 500 spike signals strong bull trend 11:23 a.m. Dec. 19, 2014 - Michael Ashbaugh
What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Actavis to buy Allergan in $66 billion deal 9:35 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Actavis confirms to buy Allergan in $66 billion deal 9:30 a.m. Nov. 17, 2014 - Ciara Linnane
Actavis, Allergan close to a deal 8:33 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Allergan, Actavis near cash-and-stock deal: WSJ 1:48 p.m. Nov. 16, 2014 - Andria Cheng
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn
U.S. M&A Seen Staying Robust In 2015, Fueled By Oil 5:38 p.m. Dec. 29, 2014 - Investors Business Daily
The Allergan Acquisition Is A Game-Changer For Actavis: Stock Could Double In Five Years 3:57 p.m. Dec. 29, 2014 - Seeking Alpha
Actavis' Alzheimer's Drug Approved; Bystolic Gets CRL - Analyst Blog 1:20 p.m. Dec. 26, 2014 - Zacks.com
The Bests and Bloopers From the Year in Deal Making 10:04 p.m. Dec. 25, 2014 - The Wall Street Journal Interactive Edition
FDA clears Adamas Alzheimer's drug 8:52 a.m. Dec. 24, 2014 - Seeking Alpha
Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog 6:05 p.m. Dec. 23, 2014 - Zacks.com
Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst Blog 5:45 p.m. Dec. 23, 2014 - Zacks.com
Actavis' Antibiotic a Step Closer to EU Nod, CHMP Positive - Analyst Blog 5:51 p.m. Dec. 22, 2014 - Zacks.com
Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive 5:23 p.m. Dec. 22, 2014 - Investors Business Daily
Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - Analyst Blog 4:30 p.m. Dec. 22, 2014 - Zacks.com
Energy Sector Seen as Biggest Risk to Deal Flow in 2015 9:00 a.m. Dec. 22, 2014 - FOXBusiness
Actavis plc (ACT): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 22, 2014 - Zacks.com
Actavis 8-K Shows $1B Revolving Credit Facility Replacing Existing $750M Pact; Term Loan Credit Pact In 2 Tranches Of $2.75B Each 5:43 a.m. Dec. 22, 2014 - benzinga.com
10 Biggest Mergers and Acquisitions of 2014 3:15 a.m. Dec. 22, 2014 - InvestorPlace.com
Merrill Lynch Top Healthcare Stock Picks for 2015 2:00 p.m. Dec. 19, 2014 - 247WallSt.com
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo 10:53 a.m. Dec. 19, 2014 - Seeking Alpha
Baidu, Alibaba Among Top World Stocks Building Bases 5:09 p.m. Dec. 18, 2014 - Investors Business Daily
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog 4:45 p.m. Dec. 18, 2014 - Zacks.com
9 Big Stocks That Doubled in 2014 11:19 a.m. Dec. 18, 2014 - 247WallSt.com
Tetraphase Jumps As 'Superbug' Drug Scores In Trial 10:54 a.m. Dec. 18, 2014 - Investors Business Daily
Timing is Crucial, Upside Analysis: Research Reports on Alder, Sky Solar, CNinsure, Raytheon, and Actavis 9:00 a.m. Dec. 29, 2014 - PR Newswire - PRF
Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 1:15 p.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride 8:00 a.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer 9:24 a.m. Dec. 22, 2014 - PR Newswire - PRF
Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults 4:15 p.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference 9:00 a.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition 7:30 a.m. Dec. 16, 2014 - PR Newswire - PRF
Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR 3:11 p.m. Dec. 15, 2014 - PR Newswire - PRF
Actavis Launches Generic Version of Celebrex® 9:28 a.m. Dec. 10, 2014 - PR Newswire - PRF
Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 4:46 p.m. Dec. 5, 2014 - PR Newswire - PRF
No Wrinkles in Actavis' $66 Billion Deal to Buy Botox Maker Allergan, an Industrial Info News Alert 6:15 a.m. Dec. 3, 2014 - Marketwired
Stock Updates on Pharma Services - Avanir Pharma, Zoetis, Allergan, Mallinckrodt, and Actavis 8:30 a.m. Nov. 25, 2014 - PR Newswire - PRF
Critical Alerts For Gold Fields, Actavis, Trina Solar Limited, Alcoa and Herbalife Released By InvestorsObserver 9:31 a.m. Nov. 19, 2014 - PR Newswire - PRF
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 10:32 a.m. Nov. 17, 2014 - PR Newswire - PRF
Valeant Comments On Allergan Announcement 9:29 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue 9:15 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer 8:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients 8:00 a.m. Nov. 13, 2014 - PR Newswire - PRF
Actavis Names Maria Teresa Hilado Chief Financial Officer 4:15 p.m. Nov. 10, 2014 - PR Newswire - PRF
Eight charts plot the year in finance 6:00 a.m. Today - Ophir Gottlieb
Here are the best S&P 500 stocks and sectors of 2014 1:52 p.m. Dec. 29, 2014 - Philip van Doorn
2014 was the year that all predictions were wrong 11:29 a.m. Dec. 26, 2014 - Marek Fuchs
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Adamas' stock soars after dementia treatment approval 8:24 a.m. Dec. 24, 2014 - Tomi Kilgore
Second 2% S&P 500 spike signals strong bull trend 11:23 a.m. Dec. 19, 2014 - Michael Ashbaugh
What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Actavis to buy Allergan in $66 billion deal 9:35 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Actavis confirms to buy Allergan in $66 billion deal 9:30 a.m. Nov. 17, 2014 - Ciara Linnane
Actavis, Allergan close to a deal 8:33 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Allergan, Actavis near cash-and-stock deal: WSJ 1:48 p.m. Nov. 16, 2014 - Andria Cheng
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn
U.S. M&A Seen Staying Robust In 2015, Fueled By Oil 5:38 p.m. Dec. 29, 2014 - Investors Business Daily
The Allergan Acquisition Is A Game-Changer For Actavis: Stock Could Double In Five Years 3:57 p.m. Dec. 29, 2014 - Seeking Alpha
Actavis' Alzheimer's Drug Approved; Bystolic Gets CRL - Analyst Blog 1:20 p.m. Dec. 26, 2014 - Zacks.com
The Bests and Bloopers From the Year in Deal Making 10:04 p.m. Dec. 25, 2014 - The Wall Street Journal Interactive Edition
FDA clears Adamas Alzheimer's drug 8:52 a.m. Dec. 24, 2014 - Seeking Alpha
Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog 6:05 p.m. Dec. 23, 2014 - Zacks.com
Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst Blog 5:45 p.m. Dec. 23, 2014 - Zacks.com
Actavis' Antibiotic a Step Closer to EU Nod, CHMP Positive - Analyst Blog 5:51 p.m. Dec. 22, 2014 - Zacks.com
Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive 5:23 p.m. Dec. 22, 2014 - Investors Business Daily
Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - Analyst Blog 4:30 p.m. Dec. 22, 2014 - Zacks.com
Energy Sector Seen as Biggest Risk to Deal Flow in 2015 9:00 a.m. Dec. 22, 2014 - FOXBusiness
Actavis plc (ACT): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 22, 2014 - Zacks.com
Actavis 8-K Shows $1B Revolving Credit Facility Replacing Existing $750M Pact; Term Loan Credit Pact In 2 Tranches Of $2.75B Each 5:43 a.m. Dec. 22, 2014 - benzinga.com
10 Biggest Mergers and Acquisitions of 2014 3:15 a.m. Dec. 22, 2014 - InvestorPlace.com
Merrill Lynch Top Healthcare Stock Picks for 2015 2:00 p.m. Dec. 19, 2014 - 247WallSt.com
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo 10:53 a.m. Dec. 19, 2014 - Seeking Alpha
Baidu, Alibaba Among Top World Stocks Building Bases 5:09 p.m. Dec. 18, 2014 - Investors Business Daily
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog 4:45 p.m. Dec. 18, 2014 - Zacks.com
9 Big Stocks That Doubled in 2014 11:19 a.m. Dec. 18, 2014 - 247WallSt.com
Tetraphase Jumps As 'Superbug' Drug Scores In Trial 10:54 a.m. Dec. 18, 2014 - Investors Business Daily
Timing is Crucial, Upside Analysis: Research Reports on Alder, Sky Solar, CNinsure, Raytheon, and Actavis 9:00 a.m. Dec. 29, 2014 - PR Newswire - PRF
Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 1:15 p.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride 8:00 a.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer 9:24 a.m. Dec. 22, 2014 - PR Newswire - PRF
Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults 4:15 p.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference 9:00 a.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition 7:30 a.m. Dec. 16, 2014 - PR Newswire - PRF
Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR 3:11 p.m. Dec. 15, 2014 - PR Newswire - PRF
Actavis Launches Generic Version of Celebrex® 9:28 a.m. Dec. 10, 2014 - PR Newswire - PRF
Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 4:46 p.m. Dec. 5, 2014 - PR Newswire - PRF
No Wrinkles in Actavis' $66 Billion Deal to Buy Botox Maker Allergan, an Industrial Info News Alert 6:15 a.m. Dec. 3, 2014 - Marketwired
Stock Updates on Pharma Services - Avanir Pharma, Zoetis, Allergan, Mallinckrodt, and Actavis 8:30 a.m. Nov. 25, 2014 - PR Newswire - PRF
Critical Alerts For Gold Fields, Actavis, Trina Solar Limited, Alcoa and Herbalife Released By InvestorsObserver 9:31 a.m. Nov. 19, 2014 - PR Newswire - PRF
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 10:32 a.m. Nov. 17, 2014 - PR Newswire - PRF
Valeant Comments On Allergan Announcement 9:29 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue 9:15 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer 8:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients 8:00 a.m. Nov. 13, 2014 - PR Newswire - PRF
Actavis Names Maria Teresa Hilado Chief Financial Officer 4:15 p.m. Nov. 10, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼